Zobrazeno 1 - 10
of 82
pro vyhledávání: '"K Roger Aoki"'
Autor:
Birgitte P S Jacky, Patton E Garay, Jérôme Dupuy, Jeremy B Nelson, Brian Cai, Yanira Molina, Joanne Wang, Lance E Steward, Ron S Broide, Joseph Francis, K Roger Aoki, Raymond C Stevens, Ester Fernández-Salas
Publikováno v:
PLoS Pathogens, Vol 9, Iss 5, p e1003369 (2013)
Botulinum neurotoxin serotype A (BoNT/A) causes transient muscle paralysis by entering motor nerve terminals (MNTs) where it cleaves the SNARE protein Synaptosomal-associated protein 25 (SNAP25206) to yield SNAP25197. Cleavage of SNAP25 results in bl
Externí odkaz:
https://doaj.org/article/0af89e3fbf6f4f00b8e336144aea2833
Autor:
Ester Fernández-Salas, Joanne Wang, Yanira Molina, Jeremy B Nelson, Birgitte P S Jacky, K Roger Aoki
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49516 (2012)
Botulinum neurotoxin serotype A (BoNT/A), a potent therapeutic used to treat various disorders, inhibits vesicular neurotransmitter exocytosis by cleaving SNAP25. Development of cell-based potency assays (CBPAs) to assess the biological function of B
Externí odkaz:
https://doaj.org/article/be97dd5401b442ad9840847343a9e930
Autor:
Catherine Rhéaume, Brian B. Cai, Joanne Wang, Ester Fernández-Salas, K. Roger Aoki, Joseph Francis, Ron S. Broide
Publikováno v:
Toxins, Vol 7, Iss 7, Pp 2354-2370 (2015)
Botulinum neurotoxin type-A (BoNT/A), as onabotulinumtoxinA, is approved globally for 11 major therapeutic and cosmetic indications. While the mechanism of action for BoNT/A at the presynaptic nerve terminal has been established, questions remain reg
Externí odkaz:
https://doaj.org/article/786123d6a1264291abc55bfe46bf0024
Autor:
M. Zouhair Atassi, Tandy Hastings-Ison, K. Roger Aoki, Philip R. Deitiker, Minako Oshima, H Kerr Graham
Publikováno v:
Journal of Neuroimmunology. 306:31-39
We have conducted a 26-month-long comparative study involving young patients (2-6years old) with a clinical diagnosis of spastic equinus secondary to cerebral palsy who have been treated with BoNT/A (BOTOX®, Allergan) tri-annually or annually. Serum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ade073a366a31e349553951f5baeae5
https://doi.org/10.1016/j.jneuroim.2017.02.014
https://doi.org/10.1016/j.jneuroim.2017.02.014
Autor:
K. Roger Aoki, Ron S. Broide, Joseph Francis, John Rubino, Maria C. Ardila, Meenakshi S. Brown, Nicholson Gregory
Publikováno v:
Toxicon. 71:18-24
Botulinum neurotoxins (BoNT) are approved for a number of therapeutic indications, including blepharospasm, cervical dystonia and hyperhidrosis, and have also shown efficacy in a variety of pain disorders. The potency of any given BoNT preparation ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7757f23112c61d1c2a50a24fb23b74b9
https://doi.org/10.1016/j.toxicon.2013.05.004
https://doi.org/10.1016/j.toxicon.2013.05.004
Publikováno v:
Neuropharmacology 70, 287-295 (2013). doi:10.1016/j.neuropharm.2013.02.012
In search of a basis for the impressive potency of an endoprotease that cleaves SNAP-25, botulinum neurotoxin type A (BoNT/A), in treating numerous diseases due to hyper-active autonomic nerves, truncation of its target and inhibition of neurotransmi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::317a38f6ad08566639e25f14f4de7d13
https://doi.org/10.1016/j.neuropharm.2013.02.012
https://doi.org/10.1016/j.neuropharm.2013.02.012
Autor:
Jianghui Meng, J. Oliver Dolly, Jiafu Wang, Gary W. Lawrence, K. Roger Aoki, Larry A. Wheeler, Tomas H. Zurawski
Publikováno v:
The FASEB Journal. 26:5035-5048
Botulinum neurotoxin (BoNT) A or E and tetanus toxin (TeTx) bind to motor-nerve endings and undergo distinct trafficking; their light-chain (LC) proteases cleave soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) peripher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eccb2f760fb15819620a921efd0dbff0
https://doi.org/10.1096/fj.12-210112
https://doi.org/10.1096/fj.12-210112
Autor:
J. Oliver Dolly, MacDara Bodeker, Tomas H. Zurawski, Jiafu Wang, Sanjay V. Boddul, K. Roger Aoki, Jianghui Meng
Publikováno v:
Biochemical Journal. 444:59-67
Various human neurogenic hyper-excitability disorders are successfully treated with type A or B BoNT (botulinum neurotoxin). The BoNT/A complex is widely used because of its longer-lasting benefits; also, autonomic side-effects are more often reporte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8c4511698f485af9a440a3fdb7da2a4
https://doi.org/10.1042/bj20120100
https://doi.org/10.1042/bj20120100
Publikováno v:
Immunobiology. 217:1-7
We investigated in two inbred mouse strains the submolecular recognition of botulinum neurotoxin type A (BoNT/A) by Abs (B cells) and by T lymphocytes. For mapping, we employed a set of overlapping synthetic peptides that encompassed the entire light
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c617790f486729d4c28eda17b6470e
https://doi.org/10.1016/j.imbio.2011.09.001
https://doi.org/10.1016/j.imbio.2011.09.001
Publikováno v:
Biochemical Journal. 441:443-452
Intracellular protein transport routes can be studied using toxins that exploit these to enter cells. BoNTA (botulinum neurotoxin type A) is a protease that binds to peripheral nerve terminals, becomes endocytosed and causes prolonged blockade of tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6245c41312a7d671d901ca477b458a5
https://doi.org/10.1042/bj20111117
https://doi.org/10.1042/bj20111117